Great steps forward this week as the results of the PRECISION Study were published in the New England Journal of Medicine. The PRECISION Study has looked at mpMRI vs TRUS biopsy for prostate cancer diagnosis.
Urology Partners have been using mpMRI scanning as part of our prostate cancer diagnosis for five years and it was a privilege to work with colleagues on this study and get the results which will change the pathway for prostate cancer diagnosis.
Richard Hindley commented "I am so proud that Basingstoke has been able to contribute to such an International collaboration - the results published in the New England Journal of Medicine have confirmed that a targeted biopsy approach, using mpMRI scanning, in prostate cancer detection leads to better results."
"The ideal test for prostate cancer would be minimally invasive, have few side effects, identify a high proportion of men who would benefit from treatment and minimize the identification of men with clinically insignificant cancer in order to prevent overtreatment".
"PRECISION has demonstrated this and furthermore, nearly 1/3 of men will avoid unnecessary biopsy.”
Read the full article in the NEJM here